AF
NGM

Amalgamated Financial’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Amalgamated Financial’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$60K Buy
+3,933
New +$61.3K ﹤0.01% 2337

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Amalgamated Financial's NGM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2022: 3,933 shares worth $60K. The stake represents ﹤0.01% of the portfolio and ranks #2337 among its holdings.

114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

  • Amalgamated Financial held 3,933 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $60K as of Q1 2022.
  • NGM Biopharmaceuticals, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2337 holding.
  • 114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.